Spotlight: Biotech Companies in the “Big 3” Regions Rake in the Cash

 

BioWeekSF will soon be here again — January 5-10, 2019 — the week of the J.P. Morgan Healthcare Conference and 20 other events and forums. In preparation, the week’s premium online guide, BioWeekSF.com, is showcasing a series of reports and other resources focusing on financing and dealmaking.

This feature is from DealForma, the biopharma database providing you comprehensive information and analyst support hours to help you be more confident using quality data in your business development research.


Introduction:

Data for the this analysis was compiled using the DealForma database; specifically the companies and venture funding sections. We used company location data tagged with the three major U.S. biotech hubs along with primary therapeutic and technology focus areas. All data are based on publicly disclosed figures. We invite you to answer interesting questions using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

Location, Location, Location: Real estate costs a lot in the three largest biotech hubs, but it’s a charm for raising capital. Biotech companies raised $37.4 billion globally in 1027 rounds of venture financing over the past four years from 2015 through the third quarter of 2018 and companies located in the San Francisco Bay Area, Greater Boston area, and San Diego County accounted for 55 percent of the total raised and 46 percent of the financing activity. The data comes from DealForma’s extensive database and research capabilities.”

Full blogpost